We are live on ! Find out more
BLRX

BioLineRX
BLRX

26 hedge funds and large institutions have $34.9M invested in BioLineRX in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

378% more capital invested

Capital invested by funds: $7.3M → $34.9M (+$27.6M)

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

18% more funds holding

Funds holding: 22 → 26 (+4)

0.07% more ownership

Funds ownership: 0.02% → 0.1% (+0.07%)

Holders
26
Holders Change
+4
Holders Change %
+18.18%
% of All Funds
0.65%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
9
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$18.8M
2
SM
Sabby Management
Florida
+$3.37M
3
SM
Senvest Management
New York
+$3.23M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.72M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.55M

Top Sellers

Rank Fund Capital Flow
1
MC
Menta Capital
California
-$95K
2
Jane Street
Jane Street
New York
-$15K
3
UBS Group
UBS Group
Switzerland
-$14K
4
NFG
Next Financial Group
Texas
-$9.01K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.29K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$16.8M +$18.8M +29,167 New
SM
2
Senvest Management
New York
$7.47M +$3.23M +5,023 +63%
SM
3
Sabby Management
Florida
$3.02M +$3.37M +5,236 New
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$2.16M +$1.72M +2,679 +250%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$1.39M +$1.55M +2,404 New
O
6
OrbiMed
New York
$998K – – –
DCM
7
DAFNA Capital Management
California
$961K +$1.07M +1,667 New
Morgan Stanley
8
Morgan Stanley
New York
$737K +$162K +252 +25%
Deutsche Bank
9
Deutsche Bank
Germany
$342K +$154K +239 +67%
OM
10
Opaleye Management
Massachusetts
$240K – – –
VKH
11
Virtu KCG Holdings
New York
$168K +$165K +256 +711%
BCA
12
Benchmark Capital Advisors
New York
$138K +$108K +167 +229%
Renaissance Technologies
13
Renaissance Technologies
New York
$126K +$141K +219 New
Citadel Advisors
14
Citadel Advisors
Florida
$102K +$92.7K +144 +436%
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$53K – – –
NFG
16
Next Financial Group
Texas
$36K -$9.01K -14 -17%
CCB
17
Cutter & Co Brokerage
Missouri
$30K +$6.44K +10 +24%
HIIFS
18
Harel Insurance Investments & Financial Services
Israel
$29K +$34.8K +54 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$24K +$27K +42 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$23K +$6.44K +10 +33%
Bank of America
21
Bank of America
North Carolina
$16K – – –
Creative Planning
22
Creative Planning
Kansas
$10K – – –
LTFS
23
Ladenburg Thalmann Financial Services
Florida
$5K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$3K -$1.29K -2 -29%
KF
25
Krilogy Financial
Missouri
$1K – – –
1
2

BLRX Hedge Fund Activity: Q1 2017 in Review

26 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2017, worth a combined $34.9M — up 378% from $7.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BLRX positions and 3 closed out — a net gain of 4 holders — while 9 added to existing stakes and 2 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $18.8M. The largest seller was Menta Capital, exiting entirely with an estimated $95K sold.

  • 26 institutional investors held BioLineRX (BLRX) as of Q1 2017, up from 22 in Q4 2016.
  • Funds reported $34.9M of BioLineRX stock for Q1 2017, up 378% quarter-over-quarter.
  • 7 funds opened new BioLineRX positions in Q1 2017 and 3 closed out, a net change of +4 holders.
  • The largest BioLineRX buyer in Q1 2017 was BVF Inc, an estimated $18.8M added.
  • The largest BioLineRX seller in Q1 2017 was Menta Capital, an estimated $95K sold.

Based on aggregated 13F filings for Q1 2017.